The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.
 
Roni Shapira
Honoraria - AstraZeneca; Medison; Merck; MSD; NeoPharm; Novartis; Roche
Consulting or Advisory Role - Clovis Oncology; Merck
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics; Protean Biodiagnostics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Protean Biodiagnostics; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
Ravit Geva
Leadership - Pyxis
Honoraria - Bristol-Myers Squibb; Janssen; Medison; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bayer; BOL Pharma; MSD; Novartis
Patents, Royalties, Other Intellectual Property - Options, BOL Pharma
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck Serono
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; EvolveImmune Therapeutics; Intensity Therapeutics; Nextcure; Torque
Consulting or Advisory Role - Abbvie; Adaptimmune; Agenus; Alligator Bioscience; Almac Diagnostics; Anaeropharma; Array BioPharma; AstraZeneca/MedImmune; BioNTech; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol-Myers Squibb; Chugai/Roche; Dragonfly Therapeutics; Genentech/Roche; Genmab; Genocea Biosciences; GI Innovation; immunocore; Innate Pharma; Lilly; Modulate Pharma; Modulate Pharma; Molecular Partners; Nektar; Newlink Genetics; Numab; Pieris Pharmaceuticals; Pierre Fabre; Seagen; SERVIER; Symphogen; Torque; Verastem; Zelluna
Other Relationship - CEC Oncology; Dava Oncology; Haymarket Media; Physicans' Education Resource
 
Harriet M. Kluger
Consulting or Advisory Role - Array BioPharma; Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Deborah J.L. Wong
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Enzychem Lifesciences (Inst); FSC Pediatrics (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)
 
Bertrand C. Liang
Employment - Kitov Pharmaceuticals
Leadership - Kitov Pharmaceuticals
Stock and Other Ownership Interests - Kitov Pharmaceuticals
Consulting or Advisory Role - Kitov Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Abcentra
Travel, Accommodations, Expenses - Kitov Pharmaceuticals
Other Relationship - Abcentra